The B-cell depleting therapy is indicated for adults with generalized myasthenia gravis and anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase antibodies.
The treatment combination was previously approved in BRCA2m-positive patients with metastatic castrate-resistant prostate cancer.
The EMA concluded that Melatomed’s benefits outweigh its risks and supported granting marketing authorizations in Germany, Austria, Denmark, and Sweden.
The third generation EGFR TKI targets EGFR mutant NSCLC, showing improved progression free survival and fewer adverse events ...
AFSOS 2025 introduced the first European reference for photobiomodulation, outlining the evidence, dosing, and clinical use in supportive cancer care.
The majority of knees without radiographic osteoarthritis experience an increase in structural damage over time, with the most frequent changes being observed in the patellofemoral joint.
The European regulator has recommended marketing approval for Ranluspec and Gotenfia after studies confirm their safety, ...
Scotland’s NHS can now offer givinostat to ambulant children with Duchenne muscular dystrophy, marking a step forward in care ...
Lower urinary tract symptoms are not associated with an increased risk for high-grade prostate cancer, rendering biopsies and ...
Respiratory syncytial virus infection in adults aged 45 years or older is significantly associated with a higher 1-year risk ...
Patients with high volumes of fat tissue around the heart may experience greater myocardial injury after acute myocardial ...
Determining which patients should receive the treatment will still require individual risk-benefit assessments, experts say.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback